Table 1.

Level of HaemSTAR involvement indicated by number of supported sites and number of patients recruited. The studies included MASCOT (a study assessing morbidity and portal circulation in patients with myeloproliferative neoplasms and splanchnic vein thrombosis), TRAIT (real world effectiveness of thrombopoietin receptor agonists in the management of immune thrombocytopenia (ITP) in the UK), FLIGHT (first line treatment pathways for newly diagnosed ITP) and the flash-mob audit of intravenous immunoglobulin use in ITP.

StudyType of studyTotal number of sitesHaemSTAR supported sites (%)Total number of patientsHaemSTAR supported patient recruitment (%)
MASCOT (pilot)Retrospective66 (100%)3131 (100%)
FLIGHTPhase III prospective randomised controlled trial3917 (44%)12454 (44%)
TRAITPhase IV retrospective158 (53%)268104 (39%)
Flash-mob auditRetrospective national audit3939 (100%)978978 (100%)